These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 7585041)

  • 81. Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit.
    Costa GL; Sandora MR; Nakajima A; Nguyen EV; Taylor-Edwards C; Slavin AJ; Contag CH; Fathman CG; Benson JM
    J Immunol; 2001 Aug; 167(4):2379-87. PubMed ID: 11490028
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Involvement of NK and NKT cells in the pathogenesis of multiple sclerosis].
    Yamamura T
    Nihon Rinsho; 2003 Aug; 61(8):1329-34. PubMed ID: 12962019
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Rolipram: antidepressant used in Europe and Japan might have promise against TNF, HIV.
    Smith D
    AIDS Treat News; 1996 Mar; (no 242):3-4. PubMed ID: 11363192
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids.
    Sinha B; Semmler J; Eisenhut T; Eigler A; Endres S
    Eur J Immunol; 1995 Jan; 25(1):147-53. PubMed ID: 7843225
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor-alpha by HLA-DR2+ T cells.
    Zipp F; Weber F; Huber S; Sotgiu S; Czlonkowska A; Holler E; Albert E; Weiss EH; Wekerle H; Hohlfeld R
    Ann Neurol; 1995 Nov; 38(5):723-30. PubMed ID: 7486863
    [TBL] [Abstract][Full Text] [Related]  

  • 86. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions.
    Barnette MS; Christensen SB; Essayan DM; Grous M; Prabhakar U; Rush JA; Kagey-Sobotka A; Torphy TJ
    J Pharmacol Exp Ther; 1998 Jan; 284(1):420-6. PubMed ID: 9435206
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Importance of interferon-gamma in protective immunity against Hymenolepis nana cysticercoids derived from challenge infection with eggs in BALB/c mice.
    Asano K; Muramatsu K
    Int J Parasitol; 1997 Nov; 27(11):1437-43. PubMed ID: 9421737
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Interleukin-10 prevents experimental allergic encephalomyelitis in rats.
    Rott O; Fleischer B; Cash E
    Eur J Immunol; 1994 Jun; 24(6):1434-40. PubMed ID: 7515815
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Age-associated changes in rat immune system: lessons learned from experimental autoimmune encephalomyelitis.
    Djikić J; Nacka-Aleksić M; Pilipović I; Stojić-Vukanić Z; Bufan B; Kosec D; Dimitrijević M; Leposavić G
    Exp Gerontol; 2014 Oct; 58():179-97. PubMed ID: 25128713
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Effect of rolipram in a murine model of acute inflammation: comparison with the corticoid dexamethasone.
    Klemm P; Harris HJ; Perretti M
    Eur J Pharmacol; 1995 Jul; 281(1):69-74. PubMed ID: 8566119
    [TBL] [Abstract][Full Text] [Related]  

  • 91. A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis.
    Aikawa Y; Tanuma N; Shin T; Makino S; Tanaka K; Matsumoto Y
    J Neuroimmunol; 1998 Aug; 89(1-2):35-42. PubMed ID: 9726823
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Production of tumor necrosis factor-alpha as a result of glia-T-cell interaction correlates with the pathogenic activity of myelin basic protein-reactive T cells in experimental autoimmune encephalomyelitis.
    Sun D; Hu X; Shah R; Zhang L; Coleclough C
    J Neurosci Res; 1996 Aug; 45(4):400-9. PubMed ID: 8872900
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Interferon-gamma and lipopolysaccharide reduce cAMP responses in cultured glial cells: reversal by a type IV phosphodiesterase inhibitor.
    Patrizio M; Costa T; Levi G
    Glia; 1995 Jun; 14(2):94-100. PubMed ID: 7558245
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis.
    Bielekova B; Richert N; Howard T; Packer AN; Blevins G; Ohayon J; McFarland HF; Stürzebecher CS; Martin R
    Mult Scler; 2009 Oct; 15(10):1206-14. PubMed ID: 19776093
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Effects of rolipram, a novel antidepressant, on monoamine metabolism in rat brain.
    Kehr W; Debus G; Neumeister R
    J Neural Transm; 1985; 63(1):1-12. PubMed ID: 4031844
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Single and repeated treatment with chlordiazepoxide and sodium valproate and head-twitch responses induced in rats with rolipram, a potential antidepressant drug.
    Cannizzaro G; Flugy A; Gagliano M; La Rocca S; Novara V
    Pharmacol Res; 1989; 21 Suppl 1():51-2. PubMed ID: 2517340
    [No Abstract]   [Full Text] [Related]  

  • 97. Evaluation of alprazolam-induced behavioural effects: differences with chlordiazepoxide after interaction with desipramine and rolipram, a cAMP phosphodiesterase inhibitor.
    Cannizzaro G; Gagliano M; La Rocca S; Novara V; Flugy A
    Pharmacol Res; 1989; 21 Suppl 1():53-4. PubMed ID: 2633187
    [No Abstract]   [Full Text] [Related]  

  • 98. Phosphodiesterase type IV inhibitors in the treatment of multiple sclerosis.
    Dinter H; Onuffer J; Faulds D; Perez HD
    J Mol Med (Berl); 1997 Feb; 75(2):95-102. PubMed ID: 9083927
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Therapeutic impact of orally administered cannabinoid oil extracts in an experimental autoimmune encephalomyelitis animal model of multiple sclerosis.
    Zhou T; Ahmad TK; Alrushaid S; Pozdirca M; Ethans K; Intrater H; Le T; Burczynski F; Kong J; Namaka M
    Biochem Biophys Res Commun; 2019 Aug; 516(2):373-380. PubMed ID: 31213295
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Ultraviolet B-induced inflammatory cytokine production, in vivo: initial pharmacological characterization.
    Griswold DE; Tzimas MN
    Inflamm Res; 1995 Aug; 44 Suppl 2():S209-10. PubMed ID: 8548403
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.